PMID- 18059220
OWN - NLM
STAT- MEDLINE
DCOM- 20071220
LR  - 20220419
IS  - 0147-5185 (Print)
IS  - 0147-5185 (Linking)
VI  - 31
IP  - 11
DP  - 2007 Nov
TI  - Differential expression of hormonal and growth factor receptors in salivary duct 
      carcinomas: biologic significance and potential role in therapeutic 
      stratification of patients.
PG  - 1645-52
AB  - Salivary duct carcinoma (SDC), a rare malignancy, manifests remarkable 
      morphologic and biologic resemblance to high-grade mammary ductal carcinoma. We 
      contend that, similar to mammary ductal carcinoma, hormones and growth factors 
      may play a role in SDCs. Our aim was to determine the incidence and clinical 
      significance of the expression of several hormone and growth factor receptors and 
      evaluate their potential in therapeutic stratification of SDC patients in the 
      largest cohort studied to date. Eighty-four archived tumor tissue blocks were 
      analyzed immunohistochemically for expression of estrogen receptor-beta (ERbeta), 
      androgen receptor (AR), and proline, glutamic acid, and leucine-rich protein-1 
      and growth factor receptors HER-2 and epidermal growth factor receptor. The 
      results were correlated with available pathologic, demographic, and clinical data 
      from 59 of 84 cases. Proline, glutamic acid, and leucine-rich protein-1, ERbeta, 
      and AR were expressed individually in 94% (71/76), 73% (57/80), and 67% (56/84) 
      of SDCs, respectively, and coexpressed in 45% (34/75). AR was expressed 
      significantly more often in SDCs of men than in SDCs of women [79% (35/57) vs. 
      33% (9/27), P<0.001]. Epidermal growth factor receptor and HER-2 were 
      overexpressed individually in 48% (40/83) and 25% (21/84), respectively, and 
      co-overexpressed in 12% (10/83). Survival decreased significantly in patients 
      with lymph node metastasis (P=0.002) and positive surgical margins (P=0.006). 
      Lack of ERbeta expression correlated with increased local and regional recurrence 
      (P=0.05 and P=0.002, respectively). Together, these results indicate that (a) 
      ERbeta down-regulation is associated with adverse clinical features, (b) lymph 
      node and surgical margin status are significant survival factors, and (c) the 
      differential expression of these hormones and growth factor receptors may assist 
      in triaging patients with SDC for novel therapies.
FAU - Williams, Michelle D
AU  - Williams MD
AD  - Department of Pathology, The University of Texas M.D. Anderson Cancer Center, 
      Houston, TX, USA.
FAU - Roberts, Dianna
AU  - Roberts D
FAU - Blumenschein, George R Jr
AU  - Blumenschein GR Jr
FAU - Temam, Stephane
AU  - Temam S
FAU - Kies, Merrill S
AU  - Kies MS
FAU - Rosenthal, David I
AU  - Rosenthal DI
FAU - Weber, Randal S
AU  - Weber RS
FAU - El-Naggar, Adel K
AU  - El-Naggar AK
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
RN  - 0 (AR protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Co-Repressor Proteins)
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (PELP1 protein, human)
RN  - 0 (Receptors, Androgen)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma/*chemistry/mortality/pathology/therapy
MH  - Co-Repressor Proteins
MH  - Cohort Studies
MH  - Down-Regulation
MH  - ErbB Receptors/analysis
MH  - Estrogen Receptor beta/analysis
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Lymph Nodes/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - *Patient Selection
MH  - Phenotype
MH  - Prognosis
MH  - Receptor, ErbB-2/analysis
MH  - Receptors, Androgen/analysis
MH  - Salivary Ducts/*chemistry/pathology
MH  - Salivary Gland Neoplasms/*chemistry/mortality/pathology/therapy
MH  - Trans-Activators/analysis
MH  - Transcription Factors
EDAT- 2007/12/07 09:00
MHDA- 2007/12/21 09:00
CRDT- 2007/12/07 09:00
PHST- 2007/12/07 09:00 [pubmed]
PHST- 2007/12/21 09:00 [medline]
PHST- 2007/12/07 09:00 [entrez]
AID - 00000478-200711000-00003 [pii]
AID - 10.1097/PAS.0b013e3180caa099 [doi]
PST - ppublish
SO  - Am J Surg Pathol. 2007 Nov;31(11):1645-52. doi: 10.1097/PAS.0b013e3180caa099.